Healthcare, Pharma & Life Sciences

Dr. Miklos Toth Named Inner Circle Life Achiever 2026 for OB/GYN Work

Image
Dr. Miklos Toth Named Inner Circle Life Achiever 2026 for OB/GYN Work

New York – October 02, 2026 -- The Inner Circle has named Miklos Toth, M.D., a Life Achiever 2026 for more than 35 years of contributions to obstetrics and gynecology, recognizing both his clinical research and humanitarian medical work in Uganda.

Dr. Toth co-founded a rural Ugandan health center that operates monthly outreach clinics

Dr. Toth and his wife, Elena Toth, established the Millennium Health Foundation and the Miklos and Elena Toth Health Center, located roughly 400 kilometers northeast of Kampala. The center delivers general obstetrics and gynecology services, with a focus on infectious disease management and 3-D Doppler ultrasound screening, operating on the first Saturday of each month and extending on-site screening to neighboring parishes. The foundation's first community initiative, Elena's Boutique, opened in July 2012 as a women's clothing shop supporting local economic independence.

Saros Therapeutics Lands Second $2M NCI Award for Cancer Immunotherapy

North Chicago, Ill. – October 02, 2026 -- Saros Therapeutics has received its second Phase II award from the National Cancer Institute, worth approximately $2 million, to advance a nanoparticle-based cancer immunotherapy toward human clinical testing.

NCI funds second two-year award for nanoparticle immunotherapy

The two-year grant will support studies needed to move Saros' experimental therapy toward an Investigational New Drug (IND) application, the company said. Saros operates within Rosalind Franklin University of Medicine and Science's (RFU) Helix 51 biomedical incubator in North Chicago, Illinois, which it joined earlier this year.

4,000 Brigham Nurses Set Oct. 14 Strike as MGB Posts $2.3B Profit

Image
4,000 Brigham Nurses Set Oct. 14 Strike as MGB Posts $2.3B Profit

Boston – October 02, 2026 -- Some 4,000 nurses at Brigham and Women's Hospital will launch an open-ended strike at 7 a.m. on October 14, 2026, in what the Massachusetts Nurses Association (MNA) calls the largest open-ended nurse strike in state history, unless Mass General Brigham (MGB) agrees to a new contract.

Nurses authorized the strike by a record 2,986-to-215 vote on September 24

The tally marks the highest yes-vote total for any nurse strike authorization in Massachusetts history, according to the MNA. The vote came as state data confirmed MGB posted a total margin of $2.3 billion, making it the most profitable hospital system in the Commonwealth for a second consecutive period.

Watercrest Names Fervil-Brown Executive Director of Pelican Landing

Image
Watercrest Names Fervil-Brown Executive Director of Pelican Landing

Vero Beach, Fla. – October 02, 2026 -- Watercrest Senior Living Group has appointed Wildi Fervil-Brown as Executive Director of Pelican Landing Assisted Living and Memory Care in Sebastian, Fla., a 63-unit assisted living and 26-unit memory care community.

Fervil-Brown brings cross-functional operational experience to the leadership post

Fervil-Brown entered the senior living industry in logistics, later moving into a Business Office Manager role overseeing financial operations, human resources and regulatory compliance. She holds master's degrees in health services administration and public health.

She advanced to Assistant Executive Director before serving as Executive Director of another senior living community, a trajectory that now places her at the helm of Pelican Landing's operations.

Heartland Dental Adds 33-Practice Foundation Dental Partners Network

Image
Heartland Dental Adds 33-Practice Foundation Dental Partners Network

Effingham, Ill. – October 02, 2026 -- Heartland Dental, the nation's largest dental support organization, has closed its affiliation with Foundation Dental Partners, adding 33 supported practices across Georgia, Tennessee, South Carolina and Kentucky to its network.

Heartland Dental extends its Southeast footprint through the Foundation affiliation

The transaction brings Foundation Dental Partners' doctor-led practices under Heartland Dental's support umbrella, giving affiliated doctors access to Heartland Dental University's clinical and leadership development programs along with operations, marketing, technology, payor relations, human resources and procurement services.

Delaware, Florida, Nemours Strike $950M Child Health Pact

Image
Delaware, Florida, Nemours Strike $950M Child Health Pact

Wilmington, Delaware – October 02, 2026 -- The Alfred I. duPont Charitable Trust, the State of Delaware, the State of Florida, and The Nemours Foundation have finalized a $950 million agreement spanning 11 years to fund children's health programs in Delaware, under a new entity called the Alfred I. duPont Charitable Fund for Delaware's Children.

New grantmaking fund will direct capital to nonprofit child-health programs statewide

The fund will operate as a separate grantmaking arm, financing nonprofit initiatives focused on children's health and well-being in Delaware. Grantmaking will extend beyond the $950 million, 11-year commitment, and will include at least $237.5 million earmarked specifically for Nemours' Delaware initiatives.

Vanda Presents Three Imsidolimab Data Sets for Rare Skin Disease GPP at EADV

Image
Vanda Presents Three Imsidolimab Data Sets for Rare Skin Disease GPP at EADV

Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.

Vanda shows imsidolimab cuts neutrophil levels rapidly in GPP patients

Poster P1769 (Abstract AS-4323) reports a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio following imsidolimab treatment in patients with generalized pustular psoriasis (GPP), a rare orphan skin condition.

Immunogenicity data on imsidolimab presented in separate poster

A second poster, P1784 (Abstract AS-2420), details the immunogenicity profile of imsidolimab in GPP patients.

ABK Biomedical Breaks Ground on Missouri Cancer Device Plant

Image
ABK Biomedical Breaks Ground on Missouri Cancer Device Plant

Ashland, Missouri – October 02, 2026 -- ABK Biomedical Inc. has launched construction of a commercial-scale manufacturing facility at Cartwright Business Park in Ashland, Missouri, designed to produce its Eye90 microspheres for liver cancer treatment. The groundbreaking, attended by Missouri Governor Mike Kehoe, follows the company's April announcement selecting Ashland for its long-term U.S. manufacturing base.

Facility targets commercial-scale output of yttrium-90 radioembolization device

The planned Good Manufacturing Practice (GMP) facility will be built for commercial-scale production of Eye90 microspheres, a clinical-stage yttrium-90 radioembolization device still under development for liver cancer treatment. The devices remain investigational and are not approved for use outside authorized clinical trials.

Rigel Pharmaceuticals Grants 35,275 RSUs to 18 New Hires

Image
Rigel Pharmaceuticals Grants 35,275 RSUs to 18 New Hires

South San Francisco, Calif. – October 02, 2026 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has granted 35,275 restricted stock units to 18 non-executive employees under its Inducement Plan.

Rigel ties new hire equity to four-year vesting schedule

The restricted stock units vest over four years, with 25% of each grant releasing annually. The Compensation Committee of Rigel's Board of Directors approved the awards as an inducement material to new employees joining the company.

Grants comply with Nasdaq Listing Rule 5635(c)(4)

Rigel issued the awards in accordance with Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity inducements to new employees outside shareholder-approved equity plans. The rule requires public disclosure of such grants, which Rigel has now made.

Emboline Logs First U.S. Commercial Use of Emboliner Protection System

Santa Cruz, Calif. – October 02, 2026 -- Emboline, Inc. completed the first commercial use of its Emboliner® Embolic Protection System in the United States on October 1, 2026, just weeks after receiving U.S. Food and Drug Administration 510(k) clearance.

Two TAVR procedures mark Emboline's commercial debut

The device was deployed during two transcatheter aortic valve implantation (TAVR) procedures performed by Tamim Nazif, MD, Co-Director of the Structural Heart and Valve Center at New York-Presbyterian/Columbia University Irving Medical Center. Dr. Nazif also serves as Co-Principal Investigator of the PROTECT H2H clinical trial, which evaluated the Emboliner's performance ahead of regulatory approval.